{
    "q": [
        {
            "docid": "11265221_2",
            "document": "5-HT3 antagonist . The 5-HT antagonists, informally known as \"setrons\", are a class of drugs that act as receptor antagonists at the 5-HT receptor, a subtype of serotonin receptor found in terminals of the vagus nerve and in certain areas of the brain. With the notable exceptions of alosetron and cilansetron, which are used in the treatment of irritable bowel syndrome, all 5-HT antagonists are antiemetics, used in the prevention and treatment of nausea and vomiting. They are particularly effective in controlling the nausea and vomiting produced by cancer chemotherapy and are considered the gold standard for this purpose.",
            "score": 246.6586434841156
        },
        {
            "docid": "11265221_17",
            "document": "5-HT3 antagonist . 5-HT receptor antagonists or serotonin antagonists were first introduced in the early 1990s, and they have become the most widely used antiemetic drugs in chemotherapy. They have also been proven safe and effective for treatment of postoperative nausea and vomiting. Serotonin (5-HT) is found widely distributed throughout the gut and the central nervous system. In the gut, 5-HT is found mostly in mucosal enterochromaffin cells. Enterochromaffin cells are sensory transducers that release 5-HT to activate intrinsic (via 5-HT1P and 5-HT receptors) and extrinsic (via 5-HT receptors) primary afferent nerves. Chemotherapeutic drugs for malignant disorders that cause vomiting have been found to cause release of large amounts of serotonin from enterochromaffin cells in the gut, serotonin acts on 5-HT receptors in the gut and brain stem.",
            "score": 236.88113474845886
        },
        {
            "docid": "37051328_4",
            "document": "5-HT2C receptor agonist . In the late 1960s, non-selective serotonin receptor antagonists demonstrated a relationship between serotonin receptors and food intake. Later, animal studies showed that serotonin receptor agonists might act as a mediator of satiety. Serotonin has been implicated as a critical factor in the short-term regulation of food intake and in promoting loss of weight associated with hyperphagia. Studies using pharmacological and genetic tools demonstrated that the 5-HT receptor subtype was one of the principal mediators through which serotonin exerts its anorectic effects in rodents. Subsequently, these receptors became a promising pharmacotherapeutic target for further investigation for the treatment of obesity. The development of 5-HT receptor knockout mice in the mid-1990s was a hallmark achievement in the identification and development of serotonergic drugs for weight loss. These knockout mice were hyperphagic, which led to obesity, partial Leptin resistance, increased adipose deposition, insulin resistance, and impaired glucose tolerance. As a result of these symptoms, the researchers identified a functional role for the receptors in serotonergic regulation of food intake and body weight. Later, 5-HT receptors were proposed as a therapeutic target for the treatment of multiple central nervous system (CNS) disorders including: psychiatric disorders, obesity, sexual dysfunction and urinary incontinence.",
            "score": 199.50325667858124
        },
        {
            "docid": "14754086_19",
            "document": "S100A10 . Most of the current drugs and treatments for depression and anxiety increase levels of serotonin transmission among neurons. Selective Serotonin Reuptake Inhibitors (SSRIs), a very successful class of drugs, are known to increase the amount of serotonin available to brain cells quite rapidly. Despite this, their therapeutic effects take a period of several weeks to months. Recent studies show that protein p11 increases the concentration of the serotonin 5-HT receptors at neuronal synapses, thereby rendering serotonin signaling much more efficient. The interaction with the serotonin 1b receptor (5-HT) and p11 can be summarized as follows: When p11 levels increases, the number of 5-HT receptors on the cell surface increase proportionately. An increase in the number of 5-HT receptors on the surface of the neuron increase the effectiveness of serotonin communication across the synapse. On the other hand, when p11 levels decrease, fewer 5-HT receptors migrate from inside the neuron to the cell membrane at the synaptic cleft, thus lowering the efficiency with which serotonin signaling can occur across the synapse. These findings suggest that, although the serotonin levels are immediately introduced via medication, the period of time within which the medicine alleviates the patient's depression most likely relies on other regulatory proteins. Thus, given protein p11's interaction with serotonin 5-HT receptors and the increasing evidence of the protein's correlation to mood disorders, this protein has been identified as a target for research in the development of future antidepressants.",
            "score": 228.44424772262573
        },
        {
            "docid": "28764_24",
            "document": "Serotonin . If irritants are present in the food, the enterochromaffin cells release more serotonin to make the gut move faster, i.e., to cause diarrhea, so the gut is emptied of the noxious substance. If serotonin is released in the blood faster than the platelets can absorb it, the level of free serotonin in the blood is increased. This activates 5-HT3 receptors in the chemoreceptor trigger zone that stimulate vomiting. The enterochromaffin cells not only react to bad food but are also very sensitive to irradiation and cancer chemotherapy. Drugs that block 5HT3 are very effective in controlling the nausea and vomiting produced by cancer treatment, and are considered the gold standard for this purpose.",
            "score": 230.86188507080078
        },
        {
            "docid": "42433109_2",
            "document": "EMA401 . EMA401 is a drug under development for the treatment of peripheral neuropathic pain. Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pains caused by lesions and other diseases affecting the somatosensory system in addition to postherpetic neuralgia. EMA401 has been implicated in alleviating pains associated with a host of neural abnormalities, ranging from excessive nerve sprouting due to damaged nerve caused by shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (ATR) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. It is the S-enantiomer form of the racemate drug EMA400. Analgesic treatments currently available for pain disorders are unsuited for severe chronic neuropathic pains. EMA401 is more effective and has virtually no central nervous system side effects in comparison to current drugs for pain relief, such as Neurotin and Lyrica. Pain pathways of the other functional systems have major molecular and mechanistic differences compared to pain pathways of the peripheral nervous system. EMA401 target proteins, angiotensin II type 2 receptors, are extremely important for nociception within the peripheral nervous system and less so for nociception within other functional systems. EMA401 is the first drug on the market that targets angiotensin II type 2 receptors (ATR) with high affinity but has a low affinity for angiotensin II type 1 receptors. Angiotensin II receptor antagonists that have existed in the pharmaceutical market have had higher affinities for angiotensin II type 1 receptors (ATR) over type 2 receptors. ATR are not involved with nociception. ATR antagonists have been mostly used for the treatment of hypertension.",
            "score": 124.84453642368317
        },
        {
            "docid": "210596_42",
            "document": "Irritable bowel syndrome . Drugs affecting serotonin (5-HT) in the intestines can help reduce symptoms. On the other hand, many IBS-D patients report that SSRI type medications exacerbate spasms and diarrhea. This is thought to be due to the large number of serotonin receptors in the gut. 5HT3 antagonists such as ondansetron are effective in postinfectious IBS and diarrhea-dominant IBS due to their blockade of serotonin on 5HT3 receptors in the gut; the reason for their benefit is believed to be that excessive serotonin in the gut is thought to play a role in the pathogenesis of some subtypes of IBS. Certain atypical antipsychotic medications, such as clozapine and olanzapine, may also provide relief due to serotonergic properties these agents possess, acting on the same receptors as other medications in this specific category. Benefits may include reduced diarrhea, reduced abdominal cramps, and improved general well-being. Any nausea present may also respond to 5HT3 antagonists owing to their antiemetic properties. Serotonin stimulates the gut motility and so agonists can help constipation-predominant irritable bowel, while antagonists can help diarrhea-predominant irritable bowel. Selective serotonin reuptake inhibitors, SSRIs, frequently prescribed for panic and/or anxiety disorder and depression, affect serotonin in the gut, as well as the brain. The bowels are highly dependent on serotonin for neural communication. \"Selective serotonin reuptake inhibitor antidepressants seem to promote global well-being in some patients with irritable bowel syndrome and, possibly, some improvement in abdominal pain and bowel symptoms, but this effect appears to be independent of improved depression. Further research is required.\"",
            "score": 219.550612449646
        },
        {
            "docid": "10534087_66",
            "document": "Serotonin\u2013norepinephrine\u2013dopamine reuptake inhibitor . 5-Hydroxytryptamine (5-HT or serotonin) is an important cell-to-cell signaling molecule found in all animal phyla. In mammals, substantial concentrations of 5-HT are present in the central and peripheral nervous systems, gastrointestinal tract and cardiovascular system. 5-HT is capable of exerting a wide variety of biological effects by interacting with specific membrane-bound receptors, and at least 13 distinct 5-HT receptor subtypes have been cloned and characterized. With the exception of the 5-HT receptor subtype, which is a transmitter-gated ion channel, 5-HT receptors are members of the 7-transmembrane G protein-coupled receptor superfamily. In humans, the serotonergic system is implicated in various physiological processes such as sleep-wake cycles, maintenance of mood, control of food intake and regulation of blood pressure. In accordance with this, drugs that affect 5-HT-containing cells or 5-HT receptors are effective treatments for numerous indications, including depression, anxiety, obesity, nausea, and migraine.",
            "score": 203.74624395370483
        },
        {
            "docid": "38468_27",
            "document": "Psilocybin . Psilocybin is rapidly dephosphorylated in the body to psilocin, which is a partial agonist for several serotonin receptors, which are also known as 5-hydroxytryptamine (5-HT) receptors. Psilocin has a high affinity for the 5-HT and 5-HT receptors in the human brain, and with a slightly lower affinity for the 5-HT receptor. Psilocin binds with low affinity to 5-HT1 receptors, including 5-HT and 5-HT. Serotonin receptors are located in numerous parts of the brain, including the cerebral cortex, and are involved in a wide range of functions, including regulation of mood and motivation. The psychotomimetic (psychosis-mimicking) effects of psilocin can be blocked in a dose-dependent fashion by the 5-HT antagonist drug ketanserin. Various lines of evidence have shown that interactions with non-5-HT receptors also contribute to the subjective and behavioral effects of the drug. For example, psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia, and some psychotomimetic symptoms of psilocin are reduced by haloperidol, a non-selective dopamine receptor antagonist. Taken together, these suggest that there may be an indirect dopaminergic contribution to psilocin's psychotomimetic effects. Unlike LSD, which binds to D2-like dopamine receptors in addition to having strong affinity for several 5-HT receptors, psilocybin and psilocin have no affinity for the dopamine D2 receptors.",
            "score": 194.66618418693542
        },
        {
            "docid": "43233600_3",
            "document": "Serotonin modulator and stimulator . SMSs were developed because there are many different subtypes of serotonin receptors (at least 15 in total are currently known) and not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT autoreceptors and 5-HT receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression. As such, a drug which combines the actions of, say, an SRI, 5-HT partial agonism, and 5-HT receptor antagonism, could, in theory, have the potential to prove more effective than pure SRIs. Alternatively, antagonism of 5-HT \u2013 a receptor that is involved in the regulation of nausea, vomiting, and the gastrointestinal tract \u2013 could counteract the undesirable increase in activation of this receptor mediated by SRIs, thereby potentially improving tolerability.",
            "score": 236.46585822105408
        },
        {
            "docid": "8884051_3",
            "document": "Dirty drug . Examples of compounds often cited as \"dirty drugs\" include chlorpromazine, olanzapine, dextromethorphan and ibogaine, all of which bind to multiple receptors or influence multiple receptor systems. There may be instances of advantages to drugs that exhibit multi-receptor activity such as the anti-addictive drug ibogaine that acts within a broad range of neurohormonal systems where activity is also exhibited by drugs commonly associated with addiction including opioids, nicotine, and alcohol. Similarly chlorpromazine is primarily used as an antipsychotic, but its strong serotonin receptor blocking effects make it useful for treating serotonergic crisis such as serotonin syndrome. Dextromethorphan for its part is widely used as a cough medication, but its other actions have led to trials for several conditions such as its use as an adjunct to analgesia, and a potential anti-addictive drug, as well as its occasional recreational use as a dissociative.",
            "score": 203.54457068443298
        },
        {
            "docid": "43173859_3",
            "document": "Science Teams Against Disease . In 2008, a Nature paper by Gonzalez-Maeso and colleagues (Icahn School of Medicine at Mount Sinai) reported that two G protein-coupled receptors (GPCRs) that are targeted by antipsychotic drugs, the serotonin 5-HT2AR and the glutamate mGlu2R receptors, come together to form a complex that is deregulated in schizophrenic patients. The functional consequences of this interaction were revealed in the 2011 Cell paper from Logothetis lab (Virginia Commonwealth University) in which this heteromeric complex was shown to be a convergent site for the activity of anti- or propsychotic drugs. According to the authors, atypical antipsychotics work through this receptor complex (5-HT2AR/ mGlu2R) and signal quite differently through the complex compared to how they signal through one or the other receptor alone. The signaling through the receptor complex could predict whether a drug would act as an antipsychotic or a pro-psychotic (e.g. the hallucinogen drug LSD).",
            "score": 181.01331508159637
        },
        {
            "docid": "18589073_2",
            "document": "Deramciclane . Deramciclane (EGIS-3886) is a non-benzodiazepine-type anxiolytic drug to treat various types of anxiety disorders. Deramciclane is a unique alternative to current anxiolytics on the market because it has a novel chemical structure and target. It acts as an antagonist at the 5-HT receptor, as an inverse agonist at the 5-HT receptor, and as a GABA reuptake inhibitor. The two serotonin receptors are G protein-coupled receptors and are two of the main excitatory serotonin receptor types. Their excitation has been implicated in anxiety and mood. Deramciclane does not affect CYP3A4 activity in metabolizing other drugs, but it is a weak inhibitor of CYP2D6. Some studies also show the drug to have moderate affinity to dopamine D2 receptors and low affinity to dopamine receptor D1. Researchers are looking for alternatives to benzodiazepines for anxiolytic use because benzodiazepine drugs have sedative and muscle relaxant side effects.",
            "score": 206.15854573249817
        },
        {
            "docid": "29500_8",
            "document": "Serotonin syndrome . Serotonin is a neurotransmitter involved in multiple states including aggression, pain, sleep, appetite, anxiety, depression, migraine, and vomiting. In humans the effects of excess serotonin were first noted in 1960 in patients receiving a monoamine oxidase inhibitor (MAOI) and tryptophan. The syndrome is caused by increased serotonin in the central nervous system. It was originally suspected that agonism of 5-HT receptors in central grey nuclei and the medulla was responsible for the development of the syndrome. Further study has determined that overstimulation of primarily the 5-HT receptors appears to contribute substantially to the condition. The 5-HT receptor may still contribute through a pharmacodynamic interaction in which increased synaptic concentrations of a serotonin agonist saturate all receptor subtypes. Additionally, noradrenergic CNS hyperactivity may play a role as CNS norepinephrine concentrations are increased in serotonin syndrome and levels appear to correlate with the clinical outcome. Other neurotransmitters may also play a role; NMDA receptor antagonists and GABA have been suggested as affecting the development of the syndrome. Serotonin toxicity is more pronounced following supra-therapeutic doses and overdoses, and they merge in a continuum with the toxic effects of overdose.",
            "score": 186.90703856945038
        },
        {
            "docid": "32955237_11",
            "document": "Chemotherapy-induced nausea and vomiting . A newer class of drugs known as the NK antagonists are a recently developed class of very efficacious drugs for controlling CINV. These drugs are often used alongside 5HT inhibitors and corticosteroids to form a very potent cocktail of antiemetics that verge on achieving a nearly complete patient response (that is, completely stopping CINV). The substance P inhibitor aprepitant (Emend), which became available in 2005, is highly effective in controlling nausea and vomiting associated with cancer chemotherapy. Aprepitant has been shown to inhibit both the acute and delayed emesis induced by cytotoxic chemotherapeutic drugs by blocking substance P landing on receptors in the brains neurons. This has been proven by Positron Emission Tomography (PET) studies, which have demonstrated that aprepitant can penetrate the brain and NK receptors in the brain. It has also been shown to increase the activity of the 5-HT receptor antagonists ondansetron and the corticosteroid dexamethasone, which are also used to prevent nausea and vomiting caused by chemotherapy. Netupitant has recently been approved by USFDA. It has also been marketed in combination with palonosetron. Rolapitant is the newest addition in the approved NK1 antagonist list. It has advantage of a very long half life, duration of action is around 150 hours. Rolapitant got its approval by USFDA in 2015.",
            "score": 183.5424828529358
        },
        {
            "docid": "14563386_13",
            "document": "Drug reaction with eosinophilia and systemic symptoms . A drug or its metabolite may also stimulate CD8 T or CD4 T cells to initiate autoimmune responses by directly binding to the T cell receptors on these T cells. Again, this binding appears to develop only on certain T cell receptors. Since the genes for these receptors are highly edited, i.e. altered to encode proteins with different amino acid sequences, and since the human population may express more than 100 trillion different (i.e. different amino acid sequences) T cell receptors while an individual express only a fraction of these, a drug's or its metabolite's ability to induce the DRESS syndrome by interacting with a T cell receptor is limited to those individuals whose T cells express a T cell receptor(s) that can interact with drug or its metabolite. Thus, only rare individuals are predisposed to develop a SCARs disorder in response to a particular drug on the bases of their expression of specific cell receptor types. While the evidence supporting these ideas is limited, one study identified the preferential presence of the TCR-V-b and complementarity determining region 3 in T cell receptors found on the T cells in the blisters of patients with allopurinol-induced DRESS syndrome. This finding is compatible with the notion that specific types of T cell receptors are involved in the development of specific drug-induced SCARs.",
            "score": 143.0926409959793
        },
        {
            "docid": "32955237_4",
            "document": "Chemotherapy-induced nausea and vomiting . Emesis is a defense mechanism controlled by the area postrema of the medulla oblongata. There are various sources of input to the vomiting center. Receptors on the floor of the fourth ventricle of the brain represent the chemoreceptor trigger zone. The chemoreceptor trigger zone contains dopamine D2 receptors, serotonin 5-HT receptors, opioid receptors, acetylcholine receptors, and receptors for substance P. Stimulation of different receptors are involved in different pathways leading to emesis. In the final common pathway, substance P, which activates the neurokinin-1 receptor, appears to be involved. Additionally, the vagal and enteric nervous system inputs transmit information regarding the state of the gastrointestinal system. Irritation of the GI mucosa by chemotherapy, radiation, distention, or acute infectious gastroenteritis activates the 5-HT receptors of these inputs. It is now widely known that cytotoxic chemotherapeutic agents cause a detectable increase in blood levels of serotonin (5-HT) and its major metabolite, 5-Hydroxyindoleacetic acid (5-HIAA). The presence of these chemicals in the blood activate 5-HT receptors in the chemoreceptor trigger zone, in turn releasing substance P, which activates NK receptors to cause an emetic response (vomiting).",
            "score": 184.62579584121704
        },
        {
            "docid": "32955237_10",
            "document": "Chemotherapy-induced nausea and vomiting . 5-HT receptor antagonists are very effective antiemetics and constitute a great advance in the management of CINV. These drugs block one or more of the nerve signals that cause nausea and vomiting. During the first 24 hours after chemotherapy, the most effective approach appears to be blocking the 5-HT nerve signal. Approved 5-HT inhibitors include dolasetron (Anzemet), granisetron (Kytril, Sancuso), and ondansetron (Zofran). Their antiemetic effect due to blockade of 5HT3 receptor on vagal afferent in the gut. in addition they also block 5-HT3 receptors in CTZ and STN. The newest 5-HT inhibitor, palonosetron (Aloxi), also prevents delayed nausea and vomiting, which can occur during the 2\u20135 days after treatment. Since some patients have trouble swallowing pills, these drugs are often available by injection, as orally disintegrating tablets, or as transdermal patches.",
            "score": 184.46811246871948
        },
        {
            "docid": "527555_28",
            "document": "Mirtazapine . Mirtazapine does not have serotonergic activity and does not cause serotonergic side effects or serotonin syndrome. This is in accordance with the fact that it is not a serotonin reuptake inhibitor or MAOI, nor a serotonin receptor agonist. There are no reports of serotonin syndrome in association with mirtazapine alone, and mirtazapine has not been found to cause serotonin syndrome in overdose. However, there are a handful of case reports of serotonin syndrome occurring with mirtazapine in combination with serotonergic drugs like SSRIs, although such reports are unusual, very rare, and do not necessarily implicate mirtazapine as causative. The addition of mirtazapine to an MAOI does not cause serotonin syndrome, and has been considered to be a safe combination. Moreover, mirtazapine may actually be useful in the treatment of serotonin syndrome, with at least one publication finding it to be effective in resolving the syndrome. This is in accordance with the fact that the 5-HT receptor is the predominant serotonin receptor thought to be involved in the pathophysiology of serotonin syndrome (with the 5-HT receptor seeming to be protective). Mirtazapine is a potent 5-HT receptor antagonist, and cyproheptadine, a drug that shares this property, mediates recovery from serotonin syndrome and is well-established clinically as an antidote against it.",
            "score": 193.47475969791412
        },
        {
            "docid": "252866_52",
            "document": "Altered state of consciousness . Extensive scientific investigation on altered states of consciousness and their relationship to drug interactions with receptors in the brain have been performed. Particularly the study of the neurotransmitter serotonin and the effects of psychedelic drugs on the brain has been intensively researched over the past sixty years. It has been hypothesized that hallucinogens act either as an antagonist or an agonist at serotonin-2A receptors and will elicit a state that shares some common phenomenological features with early acute stages of the group of schizophrenia disorders.  Findings implicate that abnormalities of serotonin function and the serotonergic system could be responsible for psychiatric disorders such as the spectrum of schizophrenia (gating) disorders and therefore, that serotonin agonist or antagonists might be useful in the treatment of e.g. schizophrenia. To investigate the underlying causative neurotransmitter mechanisms of this phenomenon, the CSTC (cortico-striato-thalamo-cortical) loop model has been formulated based on empirical neurobiological work.  It is indicated that the common hypofrontality (overactivation of frontal brain parts) and cortical activation pattern induced by serotonergic and glutamatergic hallucinogens is due to a common disruption of thalamic gating of sensory and cognitive information. The CSTC feedback loop plays a major role in gating or filtering out external and internal information to the cortex. Thereby it influences the regulation of the level of awareness and attention.  Disruption of the CSTC loop system is proposed to significantly influence information processing, e.g. the ability to screen out, inhibit filter or gate extraneous stimuli and to direct selective attention to salient features of the environment. Failures of these attentional gating mechanisms might overload patients with the excessive processing of both sensory and cognitive stimuli, which could lead to a breakdown of cognitive integrity and difficulty in distinguishing self from non-self and failure to integrate an overwhelming flood of information. Descriptive elaboration of the mentioned effects can be found in the literature on schizophrenia as well as in descriptions of hallucinogenic drug action. Despite strong evidence linking serotonin and psychosis, novel research indicates that some behavioral effects of drugs such as psilocybin appear to be independent of the classical 5-HT2A receptor-agonist actions, implicating that the model described here is not the only underlying framework at play. Interdisciplinary research enterprises have set out to study the convergence of serotonergic and glutamatergic models of psychosis and dynamic neurotransmitter interactions, derived from the study of hallucinogenic drugs, in the future.",
            "score": 188.68984270095825
        },
        {
            "docid": "23135664_2",
            "document": "SDZ SER-082 . SDZ SER-082 is a drug which acts as a mixed antagonist for the 5-HT and 5-HT serotonin receptors, with good selectivity over other serotonin receptor subtypes and slight preference for 5-HT over 5-HT. It has been used in animal studies into the behavioural effects of the different 5-HT subtypes, and how they influence the effects of other drugs such as cocaine.",
            "score": 175.42529606819153
        },
        {
            "docid": "19782967_49",
            "document": "Breast cancer classification . Receptor status is a critical assessment for all breast cancers as it determines the suitability of using targeted treatments such as tamoxifen and or trastuzumab. These treatments are now some of the most effective adjuvant treatments of breast cancer. Estrogen receptor positive (ER+) cancer cells depend on estrogen for their growth, so they can be treated with drugs to reduce either the effect of estrogen (e.g. tamoxifen) or the actual level of estrogen (e.g. aromatase inhibitors), and generally have a better prognosis. Generally, prior to modern treatments, HER+ had a worse prognosis, however HER2+ cancer cells respond to drugs such as the monoclonal antibody, trastuzumab, (in combination with conventional chemotherapy) and this has improved the prognosis significantly. Conversely, triple negative cancer (i.e. no positive receptors), lacking targeted treatments, now has a comparatively poor prognosis.",
            "score": 130.45338225364685
        },
        {
            "docid": "57762_9",
            "document": "Psychiatric medication . Antidepressants are drugs used to treat clinical depression, and they are also often used for anxiety and other disorders. Most antidepressants will hinder the breakdown of serotonin or norepinephrine or both. A commonly used class of antidepressants are called selective serotonin reuptake inhibitors (SSRIs), which act on serotonin transporters in the brain to increase levels of serotonin in the synaptic cleft. SSRIs will often take 3\u20135 weeks to have a noticeable effect, as the regulation of receptors in the brain adapts. There are multiple classes of antidepressants which have different mechanisms of action. Another type of antidepressant is a monoamine oxidase inhibitor, which is thought to block the action of Monoamine oxidase, an enzyme that breaks down serotonin and norepinephrine. MAOIs are not used as first-line treatment due to the risk of hypertensive crisis related to the consumption of foods containing the amino acid tyramine.",
            "score": 172.45313799381256
        },
        {
            "docid": "4786873_10",
            "document": "Treatment of mental disorders . In addition of atypical antipsychotics in cases of inadequate response to antidepressant therapy is an increasingly popular strategy that is well supported in the literature, though these medications may result in greater discontinuation due to adverse events. Aripiprazole was the first drug approved by the US Food and Drug Administration for adjunctive treatment of MDD in adults with inadequate response to antidepressant therapy in the current episode. Recommended doses of aripiprazole range from 2\u00a0mg/d to 15\u00a0mg/d based on 2 large, multicenter randomized, double-blind, placebo-controlled studies, which were later supported by a third large trial. Most conventional antipsychotics, such as the phenothiazines, work by blocking the D2 Dopamine receptors. Atypical antipsychotics, such as clozapine block both the D2 Dopamine receptors as well as 5HT2A serotonin receptors. Atypical antipsychotics are favored over conventional antipsychotics because they reduce the prevalence of pseudoparkinsonism which causes tremors and muscular rigidity similar to Parkinson\u2019s disease. The most severe side effect of antipsychotics is agranulocytosis, a depression of white blood cell count with unknown cause, and some patients may also experience photosensitivity.",
            "score": 134.75482380390167
        },
        {
            "docid": "2859835_22",
            "document": "Metabotropic glutamate receptor . Since metabotropic glutamate receptors are involved in a variety of functions, abnormalities in their expression can contribute to disease. For example, studies with mutant mice have suggested that mutations in expression of mGluR may be involved in the development of certain types of cancer. In addition, manipulating mGluRs can be useful in treating some conditions. For example, clinical trial suggested that an mGlu agonist, LY354740, was effective in the treatment of generalized anxiety disorder. Also, some researchers have suggested that activation of mGluR could be used as a treatment for Parkinson's disease. Most recently, Group I mGluRs, have been implicated in the pathogenesis of Fragile X, a type of autism, and a number of studies are currently testing the therapeutic potential of drugs that modify these receptors.  There is also growing evidence that group II metabotropic glutamate receptor agonists may play a role in the treatment of schizophrenia. Schizophrenia is associated with deficits in cortical inhibitory interneurons that release GABA and synaptic abnormalities associated with deficits in NMDA receptor function. These inhibitory deficits may impair cortical function via cortical disinhibition and asynchrony. The drug LY354740 (also known as Eglumegad, an mGlu agonist) was shown to attenuate physiologic and cognitive abnormalities in animal and human studies of NMDA receptor antagonist and serotonergic hallucinogen effects, supporting the subsequent clinical evidence of efficacy for an mGluR agonist in the treatment of schizophrenia. The same drug has been shown to interfere in the hypothalamic\u2013pituitary\u2013adrenal axis, with chronic oral administration of this drug leading to markedly reduced baseline cortisol levels in bonnet macaques (Macaca radiata); acute infusion of LY354740 resulted in a marked diminution of yohimbine-induced stress response in those animals. LY354740 has also been demonstrated to act on the metabotropic glutamate receptor 3 (GRM3) of human adrenocortical cells, downregulating aldosterone synthase, CYP11B1, and the production of adrenal steroids (i.e. aldosterone and cortisol).",
            "score": 120.21201539039612
        },
        {
            "docid": "28972840_4",
            "document": "Clinical neurochemistry . The most basic and fundamental neurological phenomena in neuropharmacology is the binding of a drug or neurologically active substance to a cellular target. One assay to determine the extent at which a ligand binds to its receptor is the radioligand binding assay (RBA), in which specific binding of a radioactively-labeled ligand is denoted by the difference between saturated and non-saturated tissue samples. While the RBA assay assumes that the tissue prepared has just one molecular target per ligand, in actuality this may not be the case. For example, serotonin binds to many diverse serotonin receptors which makes the RIA assay quite difficult to interpret. Because many receptors are essentially enzymes, the field of pharmakinetics utilizes the Michaelis-Menten equation to describe drug affinity (dissociation constant K) and total binding (B). Although K and B can be determined pictorally in a normal or logarithmic plot of ligand binding vs drug concentration, Scatchard plots allow for mathematical representation of several ligand binding sites, each with its own K. Drug potency is the measure of binding strength between a drug and a specific molecular target, whereas drug efficacy describes the biological effect exerted by the drug itself, at either a cellular or organismal level. Because drugs range widely in their potency and efficacy, drugs have been categorized on the spectrum of agonists and antagonists. \"Agonists\" bind to receptors and elicit the same effects as an endogenous neurotransmitter. For example, morphine is an agonist of the opioid receptor family. Conversely, \"antagonists\" bind to a receptor and elicit no cellular change. Naloxone, an antagonist of the opioid receptors, exerts a biological effect only be interfering with endogenous neurotransmitter (morphine) binding. \"Inverse agonists\" bind to receptors and elicit the opposite effect that an agonist would. The spectrum of drug continuum also includes \"partial agonists\" and \"partial inverse agonists\", which comprise the wide majority of neurological clinical treatments. The ultimate clinical effect of a drug can be analyzed with a dose-response curve.",
            "score": 200.07287526130676
        },
        {
            "docid": "1661124_16",
            "document": "Cancer immunotherapy . Fc\u2019s ability to bind Fc receptors is important because it allows antibodies to activate the immune system. Fc regions are varied: they exist in numerous subtypes and can be further modified, for example with the addition of sugars in a process called glycosylation.Changes in the Fc region can alter an antibody\u2019s ability to engage Fc receptors and, by extension, will determine the type of immune response that the antibody triggers. Many cancer immunotherapy drugs, including PD-1 and PD-L1 inhibitors, are antibodies. For example, immune checkpoint blockers targeting PD-1 are antibodies designed to bind PD-1 expressed by T cells and reactivate these cells to eliminate tumors. Anti-PD-1 drugs contain not only an Fab region that binds PD-1 but also an Fc region. Experimental work indicates that the Fc portion of cancer immunotherapy drugs can affect the outcome of treatment. For example, anti-PD-1 drugs with Fc regions that bind inhibitory Fc receptors can have decreased therapeutic efficacy. Imaging studies have further shown that the Fc region of anti-PD-1 drugs can bind Fc receptors expressed by tumor-associated macrophages. This process removes the drugs from their intended targets (i.e. PD-1 molecules expressed on the surface of T cells) and limits therapeutic efficacy. Furthermore, antibodies targeting the co-stimulatory protein CD40 require engagement with selective Fc receptors for optimal therapeutic efficacy. Together, these studies underscore the importance of Fc status in antibody-based immune checkpoint targeting strategies.",
            "score": 160.12250757217407
        },
        {
            "docid": "46188763_25",
            "document": "Gold nanoparticles in chemotherapy . Gold nanoparticles have their advantages in drug vectorization. They can pack several different sizes and types of dendrimers and several different types of ligands in order to effectively treat different types of cancers. For example, research shows that 80~90% of breast cancer\u2019s tumor cells have estrogen receptors and 60~70% of prostate cancer\u2019s tumor cells have androgen receptors. These significant amount of hormone receptors play a role in intermolecular actions. This role is now used by targeting and therapeutic ligands on gold nanoparticles to target tissue-selective anti-tumor drug delivery. In order to have multiple targeting and therapeutic ligands bind with gold nanoparticles, the gold nanoparticles must first undergo polymer stabilization. Then, anti-estrogen molecules with thiolated PEG are bound to gold nanoparticles via Au-S bonds, forming thiolate protected gold nanoparticles. Docetaxel is packed into PEGylated gold nanoparticles Docetaxel is an anti-mitotic chemotherapy medicine which showing great performance in clinical trial. Docetaxel was approved by FDA, to treat several different kinds of cancer. i.e. breast cancer(include locally advanced or metastatic).",
            "score": 151.48678922653198
        },
        {
            "docid": "28649_21",
            "document": "Stevens\u2013Johnson syndrome . In addition to acting through HLA proteins to bind with a T cell receptor, a drug or its metabolite may bypass HLA proteins to bind directly to a T cell receptor and thereby stimulate CD8 T or CD4 T cells to initiate autoimmune responses. In either case, this binding appears to develop only on certain T cell receptors. Since the genes for these receptors are highly edited, i.e. altered to encode proteins with different amino acid sequences, and since the human population may express more than 100 trillion different (i.e. different amino acid sequences) T cell receptors while an individual express only a fraction of these, a drug's or its metabolite's ability to induce the DRESS syndrome by interacting with a T cell receptor is limited to those individuals whose T cells express a T cell receptor(s) that can interact with the drug or its metabolite. Thus, only rare individuals are predisposed to develop SJS in response to a particular drug on the bases of their expression of specific T cell receptor types. While the evidence supporting this T cell receptor selectivity is limited, one study identified the preferential presence of the TCR-V-b and complementarity determining region 3 in T cell receptors found on the T cells in the blisters of patients with allopurinol-induced DRESS syndrome. This finding is compatible with the notion that specific types of T cell receptors are involved in the development of specific drug-induced SCARs.",
            "score": 146.62229752540588
        },
        {
            "docid": "654168_4",
            "document": "Receptor antagonist . Biochemical receptors are large protein molecules that can be activated by the binding of a ligand such as a hormone or a drug. Receptors can be membrane-bound, as cell surface receptors, or inside the cell as intracellular receptors, such as nuclear receptors including those of the mitochondrion. Binding occurs as a result of non-covalent interactions between the receptor and its ligand, at locations called the binding site on the receptor. A receptor may contain one or more binding sites for different ligands. Binding to the active site on the receptor regulates receptor activation directly. The activity of receptors can also be regulated by the binding of a ligand to other sites on the receptor, as in allosteric binding sites. Antagonists mediate their effects through receptor interactions by preventing agonist-induced responses. This may be accomplished by binding to the active site or the allosteric site. In addition, antagonists may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity to exert their effects.",
            "score": 170.4586933851242
        },
        {
            "docid": "2643313_4",
            "document": "Dolasetron . Dolasetron is a well-tolerated drug with few side effects. Headache, dizziness, and constipation are the most commonly reported side effects associated with its use. There is a potential for prolonging of the QT interval to occur as well. There have been no significant drug interactions reported with this drug's use. Dolasetron is broken down by the liver's cytochrome P450 system and has little effect on the metabolism of other drugs broken down by this system. Intravenous dolasetron is contraindicated in Chemotherapy-induced nausea and vomiting (CINV). Doxorubicin and cyclophosphamide are as emetogenic as cisplatin, and preventive drugs should always be considered. The 5HT3 agonists are the mainstays of prevention and are frequently used in combination with other drugs such as corticosteroids and the NK1 receptor antagonist aprepitant. However, the FDA recently issued a drug communication stating that the injection form of dolasetron, a 5HT3 agonist, should no longer be used in adult or pediatric patients with CINV. Dolasetron injection can increase the risk of developing torsade de pointes, a potentially fatal abnormal heart rhythm. Patients with underlying heart conditions or existing heart rate or rhythm problems are at increased risk. Although the oral form of this agent can still be used, careful monitoring and correction of potassium and magnesium levels should be initiated prior to and during treatment. In addition, in older patients and in patients with heart failure, a slow heart rate, underlying cardiac disease, and those with renal impairment, monitoring with electrocardiography is indicated when this drug is used. Congenital long-QT syndrome and drugs that prolong the PR or QRS interval are contraindications to dolasetron therapy. Dolasetron injection may still be used for the prevention and treatment of postoperative nausea and vomiting. As per Food and Drug Administration.",
            "score": 148.9953408241272
        },
        {
            "docid": "429616_2",
            "document": "Granisetron . Granisetron is a serotonin 5-HT receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.",
            "score": 216.55347108840942
        }
    ],
    "r": [
        {
            "docid": "11265221_2",
            "document": "5-HT3 antagonist . The 5-HT antagonists, informally known as \"setrons\", are a class of drugs that act as receptor antagonists at the 5-HT receptor, a subtype of serotonin receptor found in terminals of the vagus nerve and in certain areas of the brain. With the notable exceptions of alosetron and cilansetron, which are used in the treatment of irritable bowel syndrome, all 5-HT antagonists are antiemetics, used in the prevention and treatment of nausea and vomiting. They are particularly effective in controlling the nausea and vomiting produced by cancer chemotherapy and are considered the gold standard for this purpose.",
            "score": 246.6586456298828
        },
        {
            "docid": "11265221_17",
            "document": "5-HT3 antagonist . 5-HT receptor antagonists or serotonin antagonists were first introduced in the early 1990s, and they have become the most widely used antiemetic drugs in chemotherapy. They have also been proven safe and effective for treatment of postoperative nausea and vomiting. Serotonin (5-HT) is found widely distributed throughout the gut and the central nervous system. In the gut, 5-HT is found mostly in mucosal enterochromaffin cells. Enterochromaffin cells are sensory transducers that release 5-HT to activate intrinsic (via 5-HT1P and 5-HT receptors) and extrinsic (via 5-HT receptors) primary afferent nerves. Chemotherapeutic drugs for malignant disorders that cause vomiting have been found to cause release of large amounts of serotonin from enterochromaffin cells in the gut, serotonin acts on 5-HT receptors in the gut and brain stem.",
            "score": 236.88113403320312
        },
        {
            "docid": "43233600_3",
            "document": "Serotonin modulator and stimulator . SMSs were developed because there are many different subtypes of serotonin receptors (at least 15 in total are currently known) and not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT autoreceptors and 5-HT receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression. As such, a drug which combines the actions of, say, an SRI, 5-HT partial agonism, and 5-HT receptor antagonism, could, in theory, have the potential to prove more effective than pure SRIs. Alternatively, antagonism of 5-HT \u2013 a receptor that is involved in the regulation of nausea, vomiting, and the gastrointestinal tract \u2013 could counteract the undesirable increase in activation of this receptor mediated by SRIs, thereby potentially improving tolerability.",
            "score": 236.4658660888672
        },
        {
            "docid": "28764_24",
            "document": "Serotonin . If irritants are present in the food, the enterochromaffin cells release more serotonin to make the gut move faster, i.e., to cause diarrhea, so the gut is emptied of the noxious substance. If serotonin is released in the blood faster than the platelets can absorb it, the level of free serotonin in the blood is increased. This activates 5-HT3 receptors in the chemoreceptor trigger zone that stimulate vomiting. The enterochromaffin cells not only react to bad food but are also very sensitive to irradiation and cancer chemotherapy. Drugs that block 5HT3 are very effective in controlling the nausea and vomiting produced by cancer treatment, and are considered the gold standard for this purpose.",
            "score": 230.8618927001953
        },
        {
            "docid": "14754086_19",
            "document": "S100A10 . Most of the current drugs and treatments for depression and anxiety increase levels of serotonin transmission among neurons. Selective Serotonin Reuptake Inhibitors (SSRIs), a very successful class of drugs, are known to increase the amount of serotonin available to brain cells quite rapidly. Despite this, their therapeutic effects take a period of several weeks to months. Recent studies show that protein p11 increases the concentration of the serotonin 5-HT receptors at neuronal synapses, thereby rendering serotonin signaling much more efficient. The interaction with the serotonin 1b receptor (5-HT) and p11 can be summarized as follows: When p11 levels increases, the number of 5-HT receptors on the cell surface increase proportionately. An increase in the number of 5-HT receptors on the surface of the neuron increase the effectiveness of serotonin communication across the synapse. On the other hand, when p11 levels decrease, fewer 5-HT receptors migrate from inside the neuron to the cell membrane at the synaptic cleft, thus lowering the efficiency with which serotonin signaling can occur across the synapse. These findings suggest that, although the serotonin levels are immediately introduced via medication, the period of time within which the medicine alleviates the patient's depression most likely relies on other regulatory proteins. Thus, given protein p11's interaction with serotonin 5-HT receptors and the increasing evidence of the protein's correlation to mood disorders, this protein has been identified as a target for research in the development of future antidepressants.",
            "score": 228.4442596435547
        },
        {
            "docid": "210596_42",
            "document": "Irritable bowel syndrome . Drugs affecting serotonin (5-HT) in the intestines can help reduce symptoms. On the other hand, many IBS-D patients report that SSRI type medications exacerbate spasms and diarrhea. This is thought to be due to the large number of serotonin receptors in the gut. 5HT3 antagonists such as ondansetron are effective in postinfectious IBS and diarrhea-dominant IBS due to their blockade of serotonin on 5HT3 receptors in the gut; the reason for their benefit is believed to be that excessive serotonin in the gut is thought to play a role in the pathogenesis of some subtypes of IBS. Certain atypical antipsychotic medications, such as clozapine and olanzapine, may also provide relief due to serotonergic properties these agents possess, acting on the same receptors as other medications in this specific category. Benefits may include reduced diarrhea, reduced abdominal cramps, and improved general well-being. Any nausea present may also respond to 5HT3 antagonists owing to their antiemetic properties. Serotonin stimulates the gut motility and so agonists can help constipation-predominant irritable bowel, while antagonists can help diarrhea-predominant irritable bowel. Selective serotonin reuptake inhibitors, SSRIs, frequently prescribed for panic and/or anxiety disorder and depression, affect serotonin in the gut, as well as the brain. The bowels are highly dependent on serotonin for neural communication. \"Selective serotonin reuptake inhibitor antidepressants seem to promote global well-being in some patients with irritable bowel syndrome and, possibly, some improvement in abdominal pain and bowel symptoms, but this effect appears to be independent of improved depression. Further research is required.\"",
            "score": 219.5506134033203
        },
        {
            "docid": "429616_2",
            "document": "Granisetron . Granisetron is a serotonin 5-HT receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.",
            "score": 216.553466796875
        },
        {
            "docid": "2643313_2",
            "document": "Dolasetron . Dolasetron (trade name Anzemet) is a serotonin 5-HT receptor antagonist used to treat nausea and vomiting following chemotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much antiemetic effect when symptoms are due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.",
            "score": 211.03414916992188
        },
        {
            "docid": "736392_3",
            "document": "5-HT receptor . The serotonin receptors modulate the release of many neurotransmitters, including glutamate, GABA, dopamine, epinephrine / norepinephrine, and acetylcholine, as well as many hormones, including oxytocin, prolactin, vasopressin, cortisol, corticotropin, and substance P, among others. The serotonin receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation. The serotonin receptors are the target of a variety of pharmaceutical and recreational drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.",
            "score": 210.9672088623047
        },
        {
            "docid": "14754086_10",
            "document": "S100A10 . Although the exact mechanism is unclear, p11 protein has shown to be essential in the regulation of serotonin signaling in the brain. Serotonin (5-hydroxytryptamine or 5-HT), is a neurotransmitter found in the central and peripheral nervous systems. It is involved in mechanisms responsible for memory formation and learning, but is most known for its role in the regulation muscle contraction, appetite, sleep, and mood. Varying levels of serotonin found in the brain are associated with the development of mood disorders, such as clinical depression. P11 interacts with the serotonin receptor proteins, 5-HT receptors such as 5-HT, modulating the receptor signal transduction pathways activated by the binding of serotonin. P11 also recruits the cell surface expression of the 5-HT receptor, increasing its concentration at the synapse. This results in more rapid serotonin-dependent activities. 5-HT is involved in the regulation of kinase activity in the central nervous system, phosphorylating target proteins, and facilitating endosomal activities. P11 is coexpressed with 5-HT mRNA and its protein in parts of the brain associated with depression, suggesting that their functions are linked and influence mood.",
            "score": 208.19139099121094
        },
        {
            "docid": "18589073_2",
            "document": "Deramciclane . Deramciclane (EGIS-3886) is a non-benzodiazepine-type anxiolytic drug to treat various types of anxiety disorders. Deramciclane is a unique alternative to current anxiolytics on the market because it has a novel chemical structure and target. It acts as an antagonist at the 5-HT receptor, as an inverse agonist at the 5-HT receptor, and as a GABA reuptake inhibitor. The two serotonin receptors are G protein-coupled receptors and are two of the main excitatory serotonin receptor types. Their excitation has been implicated in anxiety and mood. Deramciclane does not affect CYP3A4 activity in metabolizing other drugs, but it is a weak inhibitor of CYP2D6. Some studies also show the drug to have moderate affinity to dopamine D2 receptors and low affinity to dopamine receptor D1. Researchers are looking for alternatives to benzodiazepines for anxiolytic use because benzodiazepine drugs have sedative and muscle relaxant side effects.",
            "score": 206.15855407714844
        },
        {
            "docid": "1487780_2",
            "document": "Chemoreceptor trigger zone . The chemoreceptor trigger zone (CTZ) is an area of the medulla oblongata that receives inputs from blood-borne drugs or hormones, and communicates with other structures in the vomiting center to initiate vomiting. The CTZ is located within the area postrema, which is on the floor of the fourth ventricle and is outside of the blood\u2013brain barrier. It is also part of the vomiting center itself. The neurotransmitters implicated in the control of nausea and vomiting include acetylcholine, dopamine, histamine (H-1 receptor), substance P (NK-1 receptor), and serotonin (5-HT3 receptor). There are also opioid receptors present, which may be involved in the mechanism by which opiates cause nausea and vomiting. The blood\u2013brain barrier is not as developed here, therefore drugs such as dopamine which cannot normally enter the CNS may still stimulate the CTZ.",
            "score": 204.63002014160156
        },
        {
            "docid": "10534087_66",
            "document": "Serotonin\u2013norepinephrine\u2013dopamine reuptake inhibitor . 5-Hydroxytryptamine (5-HT or serotonin) is an important cell-to-cell signaling molecule found in all animal phyla. In mammals, substantial concentrations of 5-HT are present in the central and peripheral nervous systems, gastrointestinal tract and cardiovascular system. 5-HT is capable of exerting a wide variety of biological effects by interacting with specific membrane-bound receptors, and at least 13 distinct 5-HT receptor subtypes have been cloned and characterized. With the exception of the 5-HT receptor subtype, which is a transmitter-gated ion channel, 5-HT receptors are members of the 7-transmembrane G protein-coupled receptor superfamily. In humans, the serotonergic system is implicated in various physiological processes such as sleep-wake cycles, maintenance of mood, control of food intake and regulation of blood pressure. In accordance with this, drugs that affect 5-HT-containing cells or 5-HT receptors are effective treatments for numerous indications, including depression, anxiety, obesity, nausea, and migraine.",
            "score": 203.74624633789062
        },
        {
            "docid": "8884051_3",
            "document": "Dirty drug . Examples of compounds often cited as \"dirty drugs\" include chlorpromazine, olanzapine, dextromethorphan and ibogaine, all of which bind to multiple receptors or influence multiple receptor systems. There may be instances of advantages to drugs that exhibit multi-receptor activity such as the anti-addictive drug ibogaine that acts within a broad range of neurohormonal systems where activity is also exhibited by drugs commonly associated with addiction including opioids, nicotine, and alcohol. Similarly chlorpromazine is primarily used as an antipsychotic, but its strong serotonin receptor blocking effects make it useful for treating serotonergic crisis such as serotonin syndrome. Dextromethorphan for its part is widely used as a cough medication, but its other actions have led to trials for several conditions such as its use as an adjunct to analgesia, and a potential anti-addictive drug, as well as its occasional recreational use as a dissociative.",
            "score": 203.54457092285156
        },
        {
            "docid": "12768831_4",
            "document": "Serotonin receptor antagonist . Another subclass consists of drugs selectively acting at the 5-HT receptors, and thus are known as 5-HT antagonists. They are efficacious in treating chemotherapy-induced emesis and postoperative nausea and vomiting. They include:",
            "score": 202.251953125
        },
        {
            "docid": "28972840_4",
            "document": "Clinical neurochemistry . The most basic and fundamental neurological phenomena in neuropharmacology is the binding of a drug or neurologically active substance to a cellular target. One assay to determine the extent at which a ligand binds to its receptor is the radioligand binding assay (RBA), in which specific binding of a radioactively-labeled ligand is denoted by the difference between saturated and non-saturated tissue samples. While the RBA assay assumes that the tissue prepared has just one molecular target per ligand, in actuality this may not be the case. For example, serotonin binds to many diverse serotonin receptors which makes the RIA assay quite difficult to interpret. Because many receptors are essentially enzymes, the field of pharmakinetics utilizes the Michaelis-Menten equation to describe drug affinity (dissociation constant K) and total binding (B). Although K and B can be determined pictorally in a normal or logarithmic plot of ligand binding vs drug concentration, Scatchard plots allow for mathematical representation of several ligand binding sites, each with its own K. Drug potency is the measure of binding strength between a drug and a specific molecular target, whereas drug efficacy describes the biological effect exerted by the drug itself, at either a cellular or organismal level. Because drugs range widely in their potency and efficacy, drugs have been categorized on the spectrum of agonists and antagonists. \"Agonists\" bind to receptors and elicit the same effects as an endogenous neurotransmitter. For example, morphine is an agonist of the opioid receptor family. Conversely, \"antagonists\" bind to a receptor and elicit no cellular change. Naloxone, an antagonist of the opioid receptors, exerts a biological effect only be interfering with endogenous neurotransmitter (morphine) binding. \"Inverse agonists\" bind to receptors and elicit the opposite effect that an agonist would. The spectrum of drug continuum also includes \"partial agonists\" and \"partial inverse agonists\", which comprise the wide majority of neurological clinical treatments. The ultimate clinical effect of a drug can be analyzed with a dose-response curve.",
            "score": 200.0728759765625
        },
        {
            "docid": "37051328_4",
            "document": "5-HT2C receptor agonist . In the late 1960s, non-selective serotonin receptor antagonists demonstrated a relationship between serotonin receptors and food intake. Later, animal studies showed that serotonin receptor agonists might act as a mediator of satiety. Serotonin has been implicated as a critical factor in the short-term regulation of food intake and in promoting loss of weight associated with hyperphagia. Studies using pharmacological and genetic tools demonstrated that the 5-HT receptor subtype was one of the principal mediators through which serotonin exerts its anorectic effects in rodents. Subsequently, these receptors became a promising pharmacotherapeutic target for further investigation for the treatment of obesity. The development of 5-HT receptor knockout mice in the mid-1990s was a hallmark achievement in the identification and development of serotonergic drugs for weight loss. These knockout mice were hyperphagic, which led to obesity, partial Leptin resistance, increased adipose deposition, insulin resistance, and impaired glucose tolerance. As a result of these symptoms, the researchers identified a functional role for the receptors in serotonergic regulation of food intake and body weight. Later, 5-HT receptors were proposed as a therapeutic target for the treatment of multiple central nervous system (CNS) disorders including: psychiatric disorders, obesity, sexual dysfunction and urinary incontinence.",
            "score": 199.50326538085938
        },
        {
            "docid": "4034544_4",
            "document": "Body load . The causes of the experience of body load are unknown. However, one proposed mechanism is the stimulation of serotonergic 5-HT receptors, particularly those involved in tactile sensation and, equally importantly in many cases where nausea is experienced, those located along the lining of the digestive tract. Serotonin is heavily involved in appetite control, and over-stimulation of serotonergic receptors has been shown to cause nausea in overdoses of SSRIs or MDMA. Many psychedelics which can cause body load are partial serotonin agonists, which work by mimicking the structure of serotonin to varying degrees.",
            "score": 197.4759521484375
        },
        {
            "docid": "11265221_11",
            "document": "5-HT3 antagonist . The 5-HT receptors are present in several critical sites involved in emesis, including vagal afferents, the solitary tract nucleus (STN), and the area postrema itself. Serotonin is released by the enterochromaffin cells of the small intestine in response to chemotherapeutic agents and may stimulate vagal afferents (via 5-HT receptors) to initiate the vomiting reflex. The 5-HT receptor antagonists suppress vomiting and nausea by inhibiting serotonin binding to the 5-HT receptors. The highest concentration of 5-HT receptors in the central nervous system (CNS) are found in the STN and chemoreceptor trigger zone (CTZ), and 5-HT antagonists may also suppress vomiting and nausea by acting at these sites. The 5-HT antagonists are greatly selective and have little affinity for other receptors, such as dopamine, histamine and muscarinic acetylcholine receptors.",
            "score": 197.33949279785156
        },
        {
            "docid": "21865_25",
            "document": "Neurotransmitter . Drugs targeting the neurotransmitter of major systems affect the whole system, which can explain the complexity of action of some drugs. Cocaine, for example, blocks the re-uptake of dopamine back into the presynaptic neuron, leaving the neurotransmitter molecules in the synaptic gap for an extended period of time. Since the dopamine remains in the synapse longer, the neurotransmitter continues to bind to the receptors on the postsynaptic neuron, eliciting a pleasurable emotional response. Physical addiction to cocaine may result from prolonged exposure to excess dopamine in the synapses, which leads to the downregulation of some post-synaptic receptors. After the effects of the drug wear off, an individual can become depressed due to decreased probability of the neurotransmitter binding to a receptor. Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI), which blocks re-uptake of serotonin by the presynaptic cell which increases the amount of serotonin present at the synapse and furthermore allows it to remain there longer, providing potential for the effect of naturally released serotonin. AMPT prevents the conversion of tyrosine to L-DOPA, the precursor to dopamine; reserpine prevents dopamine storage within vesicles; and deprenyl inhibits monoamine oxidase (MAO)-B and thus increases dopamine levels.",
            "score": 196.53160095214844
        },
        {
            "docid": "989686_9",
            "document": "Fenfluramine . Fenfluramine acts primarily as a serotonin releasing agent. It increases the level of serotonin, a neurotransmitter that regulates mood, appetite and other functions. Fenfluramine causes the release of serotonin by disrupting vesicular storage of the neurotransmitter, and reversing serotonin transporter function. The drug also acts as a norepinephrine releasing agent to a lesser extent, particularly via its active metabolite norfenfluramine. At high concentrations, norfenfluramine, though not fenfluramine, also acts as a dopamine releasing agent, and so fenfluramine may do this at very high doses as well. In addition to monoamine release, while fenfluramine binds only very weakly to the serotonin 5-HT receptors, norfenfluramine binds to and activates the serotonin 5-HT and 5-HT receptors with high affinity and the serotonin 5-HT receptor with moderate affinity. The result of the increased serotonergic and noradrenergic neurotransmission is a feeling of fullness and reduced appetite.",
            "score": 196.30194091796875
        },
        {
            "docid": "250858_29",
            "document": "Tramadol . Nausea and vomiting caused by tramadol is thought to be due to activation of the 5-HT receptor via increased serotonin levels. In accordance, the 5-HT receptor antagonist metoclopramide can be used to treat tramadol-associated nausea and vomiting. Tramadol and desmetramadol themselves do not bind to the 5-HT receptor.",
            "score": 195.64541625976562
        },
        {
            "docid": "38468_27",
            "document": "Psilocybin . Psilocybin is rapidly dephosphorylated in the body to psilocin, which is a partial agonist for several serotonin receptors, which are also known as 5-hydroxytryptamine (5-HT) receptors. Psilocin has a high affinity for the 5-HT and 5-HT receptors in the human brain, and with a slightly lower affinity for the 5-HT receptor. Psilocin binds with low affinity to 5-HT1 receptors, including 5-HT and 5-HT. Serotonin receptors are located in numerous parts of the brain, including the cerebral cortex, and are involved in a wide range of functions, including regulation of mood and motivation. The psychotomimetic (psychosis-mimicking) effects of psilocin can be blocked in a dose-dependent fashion by the 5-HT antagonist drug ketanserin. Various lines of evidence have shown that interactions with non-5-HT receptors also contribute to the subjective and behavioral effects of the drug. For example, psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia, and some psychotomimetic symptoms of psilocin are reduced by haloperidol, a non-selective dopamine receptor antagonist. Taken together, these suggest that there may be an indirect dopaminergic contribution to psilocin's psychotomimetic effects. Unlike LSD, which binds to D2-like dopamine receptors in addition to having strong affinity for several 5-HT receptors, psilocybin and psilocin have no affinity for the dopamine D2 receptors.",
            "score": 194.6661834716797
        },
        {
            "docid": "11264635_7",
            "document": "Palonosetron . Palonosetron is a 5-HT antagonist, commonly known as a \"setron\". These drugs act by blocking serotonin from binding to the 5-HT receptor.",
            "score": 194.48538208007812
        },
        {
            "docid": "527555_28",
            "document": "Mirtazapine . Mirtazapine does not have serotonergic activity and does not cause serotonergic side effects or serotonin syndrome. This is in accordance with the fact that it is not a serotonin reuptake inhibitor or MAOI, nor a serotonin receptor agonist. There are no reports of serotonin syndrome in association with mirtazapine alone, and mirtazapine has not been found to cause serotonin syndrome in overdose. However, there are a handful of case reports of serotonin syndrome occurring with mirtazapine in combination with serotonergic drugs like SSRIs, although such reports are unusual, very rare, and do not necessarily implicate mirtazapine as causative. The addition of mirtazapine to an MAOI does not cause serotonin syndrome, and has been considered to be a safe combination. Moreover, mirtazapine may actually be useful in the treatment of serotonin syndrome, with at least one publication finding it to be effective in resolving the syndrome. This is in accordance with the fact that the 5-HT receptor is the predominant serotonin receptor thought to be involved in the pathophysiology of serotonin syndrome (with the 5-HT receptor seeming to be protective). Mirtazapine is a potent 5-HT receptor antagonist, and cyproheptadine, a drug that shares this property, mediates recovery from serotonin syndrome and is well-established clinically as an antidote against it.",
            "score": 193.47476196289062
        },
        {
            "docid": "4574063_2",
            "document": "5-HT2A receptor . The mammalian 5-HT receptor is a subtype of the 5-HT receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). 5-HT is short for 5-hydroxy-tryptamine, which is serotonin. This is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT may also have an inhibitory effect on certain areas such as the visual cortex and the orbitofrontal cortex. This receptor was first noted for its importance as a target of serotonergic psychedelic drugs such as LSD. Later it came back to prominence because it was also found to be mediating, at least partly, the action of many antipsychotic drugs, especially the atypical ones.",
            "score": 190.93405151367188
        },
        {
            "docid": "28764_9",
            "document": "Serotonin . The 5-HT receptors, the receptors for serotonin, are located on the cell membrane of nerve cells and other cell types in animals, and mediate the effects of serotonin as the endogenous ligand and of a broad range of pharmaceutical and hallucinogenic drugs. Except for the 5-HT receptor, a ligand-gated ion channel, all other 5-HT receptors are G-protein-coupled receptors (also called seven-transmembrane, or heptahelical receptors) that activate an intracellular second messenger cascade.",
            "score": 190.0887451171875
        },
        {
            "docid": "252866_52",
            "document": "Altered state of consciousness . Extensive scientific investigation on altered states of consciousness and their relationship to drug interactions with receptors in the brain have been performed. Particularly the study of the neurotransmitter serotonin and the effects of psychedelic drugs on the brain has been intensively researched over the past sixty years. It has been hypothesized that hallucinogens act either as an antagonist or an agonist at serotonin-2A receptors and will elicit a state that shares some common phenomenological features with early acute stages of the group of schizophrenia disorders.  Findings implicate that abnormalities of serotonin function and the serotonergic system could be responsible for psychiatric disorders such as the spectrum of schizophrenia (gating) disorders and therefore, that serotonin agonist or antagonists might be useful in the treatment of e.g. schizophrenia. To investigate the underlying causative neurotransmitter mechanisms of this phenomenon, the CSTC (cortico-striato-thalamo-cortical) loop model has been formulated based on empirical neurobiological work.  It is indicated that the common hypofrontality (overactivation of frontal brain parts) and cortical activation pattern induced by serotonergic and glutamatergic hallucinogens is due to a common disruption of thalamic gating of sensory and cognitive information. The CSTC feedback loop plays a major role in gating or filtering out external and internal information to the cortex. Thereby it influences the regulation of the level of awareness and attention.  Disruption of the CSTC loop system is proposed to significantly influence information processing, e.g. the ability to screen out, inhibit filter or gate extraneous stimuli and to direct selective attention to salient features of the environment. Failures of these attentional gating mechanisms might overload patients with the excessive processing of both sensory and cognitive stimuli, which could lead to a breakdown of cognitive integrity and difficulty in distinguishing self from non-self and failure to integrate an overwhelming flood of information. Descriptive elaboration of the mentioned effects can be found in the literature on schizophrenia as well as in descriptions of hallucinogenic drug action. Despite strong evidence linking serotonin and psychosis, novel research indicates that some behavioral effects of drugs such as psilocybin appear to be independent of the classical 5-HT2A receptor-agonist actions, implicating that the model described here is not the only underlying framework at play. Interdisciplinary research enterprises have set out to study the convergence of serotonergic and glutamatergic models of psychosis and dynamic neurotransmitter interactions, derived from the study of hallucinogenic drugs, in the future.",
            "score": 188.68983459472656
        },
        {
            "docid": "29500_8",
            "document": "Serotonin syndrome . Serotonin is a neurotransmitter involved in multiple states including aggression, pain, sleep, appetite, anxiety, depression, migraine, and vomiting. In humans the effects of excess serotonin were first noted in 1960 in patients receiving a monoamine oxidase inhibitor (MAOI) and tryptophan. The syndrome is caused by increased serotonin in the central nervous system. It was originally suspected that agonism of 5-HT receptors in central grey nuclei and the medulla was responsible for the development of the syndrome. Further study has determined that overstimulation of primarily the 5-HT receptors appears to contribute substantially to the condition. The 5-HT receptor may still contribute through a pharmacodynamic interaction in which increased synaptic concentrations of a serotonin agonist saturate all receptor subtypes. Additionally, noradrenergic CNS hyperactivity may play a role as CNS norepinephrine concentrations are increased in serotonin syndrome and levels appear to correlate with the clinical outcome. Other neurotransmitters may also play a role; NMDA receptor antagonists and GABA have been suggested as affecting the development of the syndrome. Serotonin toxicity is more pronounced following supra-therapeutic doses and overdoses, and they merge in a continuum with the toxic effects of overdose.",
            "score": 186.90704345703125
        },
        {
            "docid": "1604590_19",
            "document": "Clomipramine . The exceptionally strong serotonin reuptake inhibition of clomipramine likely precludes the possibility of its antagonism of serotonin receptors (which it binds to with more than 100-fold lower affinity than the SERT) resulting in a net decrease in signaling by these receptors. In accordance, while serotonin receptor antagonists like cyproheptadine and chlorpromazine are effective as antidotes against serotonin syndrome, clomipramine is nonetheless capable of inducing this syndrome. In fact, while all TCAs are SRIs and serotonin receptor antagonists to varying extents, the only TCAs that are associated with serotonin syndrome are clomipramine and to a lesser extent its dechlorinated analogue imipramine, which are the two most potent SRIs of the TCAs (and in relation to this have the highest ratios of serotonin reuptake inhibition to serotonin receptor antagonism). As such, whereas other TCAs can be combined with monoamine oxidase inhibitors (with caution due to the risk of hypertensive crisis from NET inhibition; sometimes done in treatment-resistant depressives), clomipramine cannot be due to the risk of serotonin syndrome and death. Unlike the case of its serotonin receptor antagonism, orthostatic hypotension is a common side effect of clomipramine, suggesting that its blockade of the \u03b1-adrenergic receptor is strong enough to overcome the stimulatory effects on the \u03b1-adrenergic receptor of its NET inhibition.",
            "score": 185.60545349121094
        },
        {
            "docid": "12768831_2",
            "document": "Serotonin receptor antagonist . A serotonin antagonist, or serotonin receptor antagonist, is a drug used to inhibit the action at serotonin (5-HT) receptors.",
            "score": 184.9564208984375
        },
        {
            "docid": "32955237_4",
            "document": "Chemotherapy-induced nausea and vomiting . Emesis is a defense mechanism controlled by the area postrema of the medulla oblongata. There are various sources of input to the vomiting center. Receptors on the floor of the fourth ventricle of the brain represent the chemoreceptor trigger zone. The chemoreceptor trigger zone contains dopamine D2 receptors, serotonin 5-HT receptors, opioid receptors, acetylcholine receptors, and receptors for substance P. Stimulation of different receptors are involved in different pathways leading to emesis. In the final common pathway, substance P, which activates the neurokinin-1 receptor, appears to be involved. Additionally, the vagal and enteric nervous system inputs transmit information regarding the state of the gastrointestinal system. Irritation of the GI mucosa by chemotherapy, radiation, distention, or acute infectious gastroenteritis activates the 5-HT receptors of these inputs. It is now widely known that cytotoxic chemotherapeutic agents cause a detectable increase in blood levels of serotonin (5-HT) and its major metabolite, 5-Hydroxyindoleacetic acid (5-HIAA). The presence of these chemicals in the blood activate 5-HT receptors in the chemoreceptor trigger zone, in turn releasing substance P, which activates NK receptors to cause an emetic response (vomiting).",
            "score": 184.62579345703125
        }
    ]
}